Skip to main content

Month: August 2020

JD.com to Report Second Quarter 2020 Financial Results on August 17, 2020

BEIJING, China, Aug. 06, 2020 (GLOBE NEWSWIRE) — JD.com, Inc. (NASDAQ: JD and HKEX: 9618), China’s leading technology driven e-commerce company transforming to become the leading supply chain based technology and service provider, today announced that it plans to release its unaudited financial results for the three months and six months ended June 30, 2020 on Monday, August 17, 2020, before the U.S. market opens.JD.com’s management will hold a conference call at 7:30 am, Eastern Time on August 17, 2020, (7:30 pm, Beijing/Hong Kong Time on August 17, 2020) to discuss financial results for the three months and six months ended June 30, 2020.Additionally, a live and archived webcast of the conference call will also be available on the Company’s investor relations website at http://ir.jd.com.About JD.com, Inc.For investor and media...

Continue reading

Vive Crop Protection and Marrone Bio Innovations join forces to bring next-generation crop protection solutions to growers

TORONTO and DAVIS, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, and Vive Crop Protection, a leader in Precision Chemistry solutions and owner of the patented Allosperse® technology, announced an agreement that will provide a suite of ground-breaking products for U.S. growers that combine a leading biological with proven conventional chemistry utilizing the unique Allosperse Delivery System.The first product to come from this joint effort will be AZterknot™ FC, a fungicide for broad crop use marketed by Vive Crop Protection. It fuses the plant health benefits of two actives: Reynoutria extract, the active ingredient in biological market-leader Regalia®, and the disease-fighting power of azoxystrobin, the...

Continue reading

Caladrius Biosciences to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 13, 2020

BASKING RIDGE, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced that it will report financial results for the three and six months ended June 30, 2020 after the close of the U.S. financial markets on Thursday, August 13, 2020.Caladrius management will host a conference call for investors beginning at 4:30 p.m. (ET) on Thursday, August 13, 2020 to discuss the financial results and provide a business update.Shareholders and other interested parties may participate in the conference call by dialing 866-595-8403 (domestic) or 706-758-9979 (international) and referencing conference ID number 2093833. The conference...

Continue reading

Yield10 Bioscience to Announce Second Quarter 2020 Financial Results and Host a Conference Call on Tuesday, August 11, 2020

WOBURN, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (NASDAQ: YTEN), an agricultural bioscience company, announced today that the Company will report its second quarter 2020 financial results and provide a corporate update on Tuesday, August 11, 2020.Management will host a conference call on Tuesday, August 11, 2020 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management’s formal remarks, there will be a question and answer session.To listen to the conference call, interested parties within the U.S. should call 1-877-709-8150. International callers should call +1-201-689-8354. The call will also be available through a live webcast, and will reference a slide deck, both of which may be accessed through the investor relations section...

Continue reading

InterDigital Announces Financial Results For Second Quarter 2020

WILMINGTON, Del., Aug. 06, 2020 (GLOBE NEWSWIRE) — InterDigital, Inc. (NASDAQ:IDCC), a mobile and video technology research and development company, today announced results for the second quarter ended June 30, 2020.Second Quarter 2020 Financial HighlightsSecond quarter 2020 recurring revenue was $85.2 million, compared to recurring revenue of $74.4 million in second quarter 2019, a 15% increase.  This increase was driven by new patent license agreements signed over the last twelve months, including with Huawei and ZTE. Second quarter 2020 total revenue was $104.5 million, compared to $75.6 million in second quarter 2019. The increase was primarily driven by the signing of a new fixed-fee patent license agreement with Huawei in second quarter 2020.Second quarter 2020 operating expenses were $72.6 million, compared to $66.7 million...

Continue reading

B2Digital Issues Shareholder Letter Outlining the Path Ahead

Tampa, FL, Aug. 06, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — B2Digital Incorporated (the “Company” or “B2Digital”) (OTCMKTS:BTDG), the premier development league for mixed martial arts (“MMA”), issues the following letter to shareholders on behalf of the CEO:Dear Valued Shareholder,Allow me to begin today by expressing our most sincere gratitude to our faithful shareholders for your loyalty, patience, and commitment. Today, I would like to provide you with a more thorough and detailed understanding of our vision, our current status and near-term prognosis, further insights into our emerging model, what we have recently accomplished, and what we are focused on achieving next.First off, we are extremely excited about the path ahead, and about returning to our pre-Covid operating assumptions, when we were just starting to ride...

Continue reading

Evoke Pharma Reports Second Quarter 2020 Financial Results

SOLANA BEACH, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2020.“The recent FDA approval of Gimoti, the first and only outpatient treatment option that bypasses the stomach to relieve symptoms in adults with acute and recurrent diabetic gastroparesis, marked the most significant milestone in our history,” said David A. Gonyer, R.Ph., President and CEO of Evoke Pharma. “We are currently focused on the commercial launch of Gimoti during the fourth quarter of 2020 with EVERSANA, our commercial partner. EVERSANA is working with us to fully implement our strategy, while leveraging their integrated suite of commercialization capabilities....

Continue reading

Phathom Pharmaceuticals Reports Second Quarter 2020 Results

FLORHAM PARK, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2020.“The second quarter was very productive for Phathom as we resumed new patient screening and enrollment in both our PHALCON-EE and PHALCON-HP Phase 3 trials and continued to make substantial progress in building our organization,” said Terrie Curran, President and Chief Executive Officer of Phathom.  “Our engagement with clinical sites has been extremely positive, and we’re encouraged by the ongoing enrollment in both trials to date.  While continuing to execute on our current development programs, we have also advanced our medical, commercial,...

Continue reading

Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer

SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) — Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the appointment of Lance Kurata as Chief Legal Officer, starting August 10, 2020.  Mr. Kurata joins Arcturus from Mintz, where he was a partner in the Corporate Group and a member of the Life Sciences Practice Group.“Lance is widely recognized as a leading biotechnology focused attorney. His deep expertise in transactions and intellectual property will be particularly valuable as Arcturus continues to drive forward our differentiated messenger RNA therapeutic and vaccine platform and our pipeline of promising...

Continue reading

Barfresh Enters Strategic Relationship with Smart Beverage

Smart Beverage Will Distribute Only Barfresh Products to Its Customers Including Over 800 SchoolsRelationship Expected to Initially Generate Revenue of $1 Million to $2 Million Annually In Current COVID-19 EnvironmentExcluding the COVID-19 Environment, Relationship Expected to Generate Revenue of $2 Million to $3 Million AnnuallyLOS ANGELES, Aug. 06, 2020 (GLOBE NEWSWIRE) — Barfresh Food Group, Inc. (the “Company” or “Barfresh”) (OTCQB: BRFH), a manufacturer of frozen, ready-to-blend and ready-to-drink beverages, announced it has entered into a strategic distribution relationship with Smart Beverage Inc., (dba Thirsty Coconut)., Inc. Smart Beverage will sell Barfresh’s full line of products, to include Twist & Go, and Bulk-Easy Pour, as well as sell and distribute Barfresh’s new range of WHIRLZ 100% juice Concentrates that...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.